ESTRO 2025 - Abstract Book

S826

Clinical - Gynaecology

ESTRO 2025

by 11%, 7% and 23%. Such dose constraints were feasible in 90% of cases. In PORT, limiting the BM V 10Gy , V 20Gy and V 35Gy to <70%, <50% and <20% could only achieve 2-6% reduction in the NTCP.